Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders

被引：14
|
作者：
Yoon, David S. [1 ]
Wu, Shung C. [1 ]
Seethala, Ramakrishna [2 ]
Golla, Rajasree [2 ]
Nayeem, Akbar [3 ]
Everlof, John G. [4 ]
Gordon, David A. [5 ]
Hamann, Lawrence G. [1 ]
Robl, Jeffrey A. [1 ]
机构：
[1] Bristol Myers Squibb Co, Res & Dev, Dept Chem, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Res & Dev, Lead Evaluat, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Res & Dev, CADD, Princeton, NJ 08543 USA
[4] Bristol Myers Squibb Co, Res & Dev, PCO Discovery Pharmaceut, Princeton, NJ 08543 USA
[5] Bristol Myers Squibb Co, Res & Dev, Dept Biol, Princeton, NJ 08543 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 21期
关键词：
11-Beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1); Enzyme inhibitor; Pyridyl sulfonamide; Type-2; diabetes; SELECTIVE INHIBITORS; VISCERAL OBESITY; POTENT; HYPERGLYCEMIA; DESIGN; MODEL; MICE;
D O I：
10.1016/j.bmcl.2014.09.012
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A previous disclosure from this lab highlighted the discovery of pyridyl amides as potent 11 beta-HSD1 inhibitors. In order to build additional novelty and polarity into this chemotype, replacement of the hydrogen-bonding carbonyl (CO) pharmacophore with the bioisosteric sulfonyl (SO2) group was examined. Despite initial comparisons suggesting the corresponding sulfonamides exhibited weaker activity versus their carbonyl counterparts, further optimization was performed in an effort to identify various potent and unique leads for the program. Judicious incorporation of polar moieties resulted in the identification of compounds with enhanced potency and lipophilicity profiles, resulting in leads with superior aqueous solubility and liver microsomal stability. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5045 / 5049
页数：5
相关论文
共 50 条
  • [41] HUMAN CARDIAC 11-BETA-HYDROXYSTEROID DEHYDROGENASE (11-BETA-HSD) IS NAD(+)-DEPENDENT AND UNIDIRECTIONAL
    SLIGHT, SH
    GOMEZSANCHEZ, CE
    GANJAM, VK
    CIRCULATION, 1995, 92 (08) : 1662 - 1662
  • [42] CLONING OF CDNA FOR SQUIRREL-MONKEY 11-BETA-HYDROXYSTEROID DEHYDROGENASE (11-BETA-HSD)
    MOORE, CCD
    MELLON, SH
    SIITERI, PK
    MILLER, WL
    CLINICAL RESEARCH, 1992, 40 (01): : A48 - A48
  • [43] 11β-hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension
    Campino, Carmen
    Carvajal, Cristian A.
    Cornejo, Javiera
    San Martin, Betty
    Olivieri, Oliviero
    Guidi, Giancesare
    Faccini, Giovanni
    Pasini, Francesco
    Sateler, Javiera
    Baudrand, Rene
    Mosso, Lorena
    Owen, Gareth I.
    Kalergis, Alexis M.
    Padilla, Oslando
    Fardella, Carlos E.
    ENDOCRINE, 2010, 37 (01) : 106 - 114
  • [44] 11β-hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension
    Carmen Campino
    Cristian A. Carvajal
    Javiera Cornejo
    Betty San Martín
    Oliviero Olivieri
    Giancesare Guidi
    Giovanni Faccini
    Francesco Pasini
    Javiera Sateler
    Rene Baudrand
    Lorena Mosso
    Gareth I. Owen
    Alexis M. Kalergis
    Oslando Padilla
    Carlos E. Fardella
    Endocrine, 2010, 37 : 106 - 114
  • [45] Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor
    Gibbs, John P.
    Emery, Maurice G.
    McCaffery, Ian
    Smith, Brian
    Gibbs, Megan A.
    Akrami, Anna
    Rossi, John
    Paweletz, Katherine
    Gastonguay, Marc R.
    Bautista, Edgar
    Wang, Minghan
    Perfetti, Riccardo
    Daniels, Oranee
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (06): : 830 - 841
  • [46] 17β-Hydroxysteroid Dehydrogenase 3 (17β-HSD3), a Regulator of 11β-Hydroxysteroid Dehydrogenase 1 (11β-HSD1) Activity in Rat Leydig Cell.
    Latif, S. A.
    Ge, R.
    Sottas, C. M.
    Shen, M.
    Morris, D. J.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [47] Discovery of novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1
    Su, Xiangdong
    Vicker, Nigel
    Trusselle, Melanie
    Halem, Heather
    Culler, Michael D.
    Potter, Barry V. L.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 301 (1-2) : 169 - 173
  • [48] ROLE OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE (HSD) AND LIVER ON DEXAMETHASONE (DEX) INACTIVATION
    WEST, SC
    MEIKLE, AW
    TYLER, FH
    CLINICAL RESEARCH, 1975, 23 (02): : A96 - A96
  • [49] 11-BETA-HYDROXYSTEROID DEHYDROGENASE AND ITS INHIBITORS IN HYPERTENSIVE PREGNANCY
    WALKER, BR
    WILLIAMSON, PM
    BROWN, MA
    HONOUR, JW
    EDWARDS, CRW
    WHITWORTH, JA
    HYPERTENSION, 1995, 25 (04) : 626 - 630
  • [50] 11β-hydroxysteroid dehydrogenase type 1 inhibitors
    Boyle, Craig D.
    Kowalski, Timothy J.
    Zhang, Lili
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 41, 2006, 41 : 127 - 140
12345